Kite Pharma enters into licensing agreement with NIH

09-06-2014

Kite Pharma enters into licensing agreement with NIH

Photo: Gil C / Shutterstock.com

Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health (NIH) that will give it the IP rights to T-cell therapies developed to treat cancer.


Kite Pharma, NCI, NIH, T-cell therapies, antigen NY-ESO-1

LSIPR